<DOC>
	<DOCNO>NCT00004228</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know regimen combination chemotherapy effective lymphoblastic lymphoma . PURPOSE : This randomized phase III trial study different regimen combination chemotherapy compare well work treat child adolescent newly diagnose stage III stage IV lymphoblastic lymphoma .</brief_summary>
	<brief_title>Combination Chemotx Treating Children Adolescents With Newly Diagnosed Stg III Stg IV Lymphoblastic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival overall survival child adolescent newly diagnose disseminate stage III IV lymphoblastic lymphoma treat 4 chemotherapy regimens* . - Determine whether treatment regimen without methotrexate maintains disease-free survival NHL/BFM 90 patient . - Determine whether intensification anthracycline cyclophosphamide improve disease-free survival patient . - Collect outcome data uniformly treat patient localized disease CNS-positive disease . - Determine whether rapid reduction tumor volume chest radiography CT scan predictive improve outcome patient treat regimen . - Determine prevalence bone marrow involvement presentation patient . - Determine whether peripheral blood replace bone marrow initial staging patient . - Determine clinical significance bone marrow peripheral blood involvement patient . NOTE : *All patient 4/2006 receive treatment Arm III regimen OUTLINE : Patients stratify disease characteristic ( disseminate lymphoblastic lymphoma v localize lymphoblastic lymphoma [ localize lymphoblastic lymphoma close accrual 10/2005 ] ) age . Patients CNS negative disseminate lymphoblastic lymphoma randomize 1 4 treatment arms* . Patients testicular involvement diagnosis nonrandomly assign arm IV receive testicular radiotherapy . Patients localize lymphoblastic lymphoma ( close accrual 10/2005 ) randomize . NOTE : *All patient 4/2006 receive treatment Arm III - Localized lymphoblastic lymphoma ( close accrual 10/2005 ) : - Induction ( 5 week ) : Patients receive vincristine IV daunorubicin IV 15 minute 2 hour day 0 , 7 , 14 , 21 ; oral prednisone day 0-27 ; asparaginase intramuscularly ( IM ) day 3 , 5 , 7 3 time week 9 dos ( day 8-21 ) . Patients also receive methotrexate intrathecally ( IT ) day 7 28 cytarabine IT day 0 . - Consolidation ( 5 week ) : Patients receive methotrexate IT day 0 , 7 , 14 , 21 follow cyclophosphamide IV 1 hour day 0 14 ; cytarabine IV day 0-3 , 7-10 , 14-17 , 21-24 ; oral mercaptopurine day 0-27 ; oral prednisone 10 day . - Interim maintenance ( 8 week ) : Patients receive methotrexate IT day 0 28 ; oral mercaptopurine day 0-41 ; oral methotrexate day 7 , 14 , 21 , 35 . - Delayed intensification ( 7 week ) : Patients receive vincristine IV doxorubicin IV 15 minute 2 hour day 0 , 7 , 14 ; asparaginase IM day 3 3 time week 6 dos ; oral dexamethasone day 0-30 ; cyclophosphamide IV 1 hour day 28 ; cytarabine IV SC day 28-31 35-38 . Patients also receive oral thioguanine day 28-41 methotrexate IT day 28 35 . - Maintenance ( 84 day course ) : Patients receive vincristine IV day 0 , 28 , 56 ; oral prednisone day 0-4 , 28-32 , 56-60 ; oral methotrexate day 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 , 70 , 77 ; oral mercaptopurine day 0-83 ; methotrexate IT day 0 . - Disseminated lymphoblastic lymphoma : - Arm I ( close accrual 4/2006 ) : Patients receive induction , consolidation , interim maintenance therapy schedule localize lymphoblastic lymphoma patient . - Delayed intensification ( 7 week ) : Patients receive vincristine IV doxorubicin IV 15 minute 2 hour day 0 , 7 , 14 , 21 ; asparaginase IM day 3 3 time week 6 dos ; oral dexamethasone day 0-28 . Patients also receive cyclophosphamide IV 1 hour day 35 ; cytarabine IV SC day 35-38 42-45 ; oral thioguanine day 35-48 ; methotrexate IT day 35 42 . - Maintenance ( 84 day course ) : Patients receive therapy localize lymphoblastic lymphoma patient , except methotrexate IT administer day 0 28 ( first 4 course ) . - Arm II ( close accrual 4/2006 ) : Patients receive consolidation , interim maintenance , maintenance therapy arm I . - Induction ( 5 week ) : Patients receive vincristine IV day 0 , 7 , 14 , 21 ; daunorubicin IV 48 hour day 0-2 ; oral prednisone day 0-27 ; asparaginase IM day 3 , 5 , 7 3 time week 9 dos ( day 8-21 ) . Patients also receive methotrexate IT day 7 28 ; cyclophosphamide IV 1 hour day 2 ; cytarabine IT day 0 . - Delayed intensification ( 7 week ) : Patients receive vincristine IV day 0 , 7 , 14 , 21 ; daunorubicin IV 48 hour day 0-2 ; asparaginase IM day 3 3 time week 6 dos ; oral dexamethasone day 0-28 . Patients also receive cyclophosphamide IV 1 hour day 2 35 ; cytarabine IV SC day 35-38 42-45 ; oral thioguanine day 35-48 ; methotrexate IT day 35 42 . - Arm III : - Induction ( 5 week ) : Patients receive vincristine IV daunorubicin IV 1 hour day 0 , 7 , 14 , 21 oral prednisone day 0-37 . Patients also receive asparaginase IM day 11 3 time week 9 dos ; methotrexate IT day 7 28 ; cytarabine IT day 0 . - Consolidation ( 5 week ) : Patients receive methotrexate IT cyclophosphamide IV 1 hour day 0 14 ; cytarabine IV SC day 0-3 , 7-10 , 14-17 , 21-24 ; oral mercaptopurine day 0-27 ; oral prednisone 10 day . - Interim maintenance ( 9 week ) : Patients receive methotrexate IT IV day 7 , 21 , 35 , 49 ; oral mercaptopurine day 0-55 ; leucovorin calcium IV 42 , 48 , 54 hour methotrexate IV . - Delayed intensification ( 10 week ) : Patients receive vincristine IV doxorubicin IV 1 hour day 0 , 7 , 14 , 21 ; asparaginase IM day 3 3 time week 6 dos ; oral dexamethasone day 0-29 . Patients also receive cyclophosphamide IV 1 hour day 35 ; cytarabine IV day 35-38 42-45 ; oral thioguanine day 35-48 ; methotrexate IT day 35 42 . - Maintenance ( 84 day course ) : Patients receive vincristine IV day 0 , 28 , 56 ; oral prednisone day 0-4 , 28-32 , 56-60 ; oral methotrexate day 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 , 70 , 77 ; oral mercaptopurine day 0-83 . - Arm IV ( close accrual 4/2006 ) : Patients receive consolidation interim maintenance therapy arm III . - Induction : Patients receive vincristine IV day 0 , 7 , 14 , 21 ; daunorubicin IV 48 hour day 0-2 ; oral prednisone day 0-37 ; asparaginase IM day 11 3 time week 9 dos ; methotrexate IT day 7 , 14 , 21 , 28 ; cyclophosphamide IV day 2 ; cytarabine IT day 0 . - Delayed intensification ( 10 week ) : Patients receive vincristine IV day 7 , 14 , 21 , 28 ; daunorubicin IV 48 hour day 0-2 ; asparaginase IM day 3 3 time week 6 dos ; oral dexamethasone day 0-29 . Patients also receive cyclophosphamide IV 1 hour day 2 35 ; cytarabine IV day 35-38 42-45 ; oral thioguanine day 35-48 ; methotrexate IT day 35 42 . - Maintenance ( 84 day course ) : Patients receive therapy arm III . Patients 1 year age CNS disease diagnosis undergo cranial radiotherapy daily 5 day week begin day 0 . Patients 2 year age undergo radiotherapy 11-14 day ( 6-9 day 1-2 year age ) . Patients follow monthly one year , every 3 month 1 year , every 6 month 1.5 year , annually thereafter . PROJECTED ACCRUAL : Approximately 250-400 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose disseminate lymphoblastic lymphoma localize lymphoblastic lymphoma* Less 25 % tumor cell bone marrow Previously untreated ( prior intrathecal cytarabine allow protocol therapy begin within 72 hour ) Stage III IV disease NOTE : *Localized lymphoblastic lymphoma close accrual 10/2005 PATIENT CHARACTERISTICS : Age : 1 30 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : Adequate cardiac function PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Emergency steroid therapy ( require ) must start within 72 hour prior protocol therapy Radiotherapy : Emergency radiotherapy ( require ) must start within 72 hour prior protocol therapy Surgery : Not specify Other : No prior therapy except emergency treatment airway obstruction and/or superior vena cava syndrome</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
</DOC>